Teladoc Health’s Stock Drops While Revenues And Bussiness Skyrocket

Buying Teladoc Health’s stock in 2022 might make some investors nervous. Because, in reality, this stock has already lost about 14%. Concerns about the end of the pandemic and how it will affect Teladoc’s profitability have caused some investors to sell the stock. But, in reality, these risks are only part of the company’s story. During the early days of the pandemic, many investors considered Teladoc a coronavirus stock due to the influx of users. But, this didn’t mean that the company would be able to capitalize on the increased usage.

Teladoc Health

Even though the pandemic ended, Teladoc Health’s business continued to grow. During Q3 of 2021, the company’s total revenue increased by 19%. According to the company, 82% of its users consider virtual visits as better than in-person visits. The company’s continued growth is expected to continue through 2030. According to Allied Market Research, the global telehealth market will reach a total of $431 billion by 2030. Teladoc Health is also projecting that its revenue will reach $4 billion in 2024. With almost 92 million customers, the company has plenty of room for further growth. It’s also projecting that its revenue will reach $4 billion in 2024. With the number of insured lives in the US increasing significantly, Teladoc has plenty of room for further growth.